Turmimax® BIO health benefits
A patented, water-dispersible Curcuma longa rhizome extract standardised to more than 95% curcuminoids - clinically studied for joint comfort, mobility and physical function.
Supports joint comfort
Supports comfortable movement and healthy knee-joint function.
WOMAC pain decreased from 8.98 at screening to 3.57 by Day 84 - a 60.25% reduction from baseline. VAS scores also improved, from 6.15 cm at screening to 5.42 cm at Day 84, while the placebo group showed no improvement.
Promotes joint flexibility
Helps reduce occasional stiffness and supports flexible movement.
WOMAC stiffness scores decreased from 6.04 at screening to 4.04 at Day 42 and 2.09 at Day 84 - a 65.40% reduction. Placebo remained largely unchanged.
Supports mobility & daily function
Supports mobility and easier daily physical activity.
WOMAC difficulty scores improved progressively, with a reported 44.69% reduction in difficulty performing daily activities by Day 84 in the Turmimax® BIO group.
Helps maintain healthy inflammatory response
Supports a balanced inflammatory response.
IL-6 decreased from 5.84 to 4.75 ng/L and Leukotriene B4 from 653.79 to 587.52 ng/L. hs-CRP and ESR also improved versus placebo over the 84-day intervention.
Supports cartilage & joint-structure health
Supports cartilage matrix integrity.
MMP-3 decreased in the Turmimax® BIO group over 84 days while it increased in placebo. Preclinical work reported preservation of COL2A1 and aggrecan with reductions in MMP-2, -3, -9 and -13.
Progression of WOMAC scores
Clinical Efficacy Progress
Measures knee-joint pain during movement, walking, and resting.
Statistical significance p < 0.01 observed across all main sub-scores by Day 84.
Clinically studied dose
The 2025 clinical study evaluated a 200 mg daily dose of Turmimax® BIO over 84 days. Finished-product use levels, claims and label copy should be confirmed against the approved clinical dossier and applicable regulatory requirements for each market.